EGFR and non-small cell lung carcinoma: Therefore, combined VEGF and EGFR inhibition represents a rational combination strategy for EGFR-mutant NSCLC treatment as VEGF and EGF share common downstream signaling pathways and may function exclusively from one another during oncogenesis and acquired therapeutic resistance [76].